VERAXA Biotech AG (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue.
VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to $50 million, are expected to support advancement of its BiTAC-TCE and BiTAC-ADC programs toward clinical development. The company recently presented preclinical data at the AACR Annual Meeting 2026 demonstrating favorable efficacy and safety characteristics for its lead BiTAC-TCE candidate.
This business combination marks a significant milestone for VERAXA, as it gains access to public capital markets to advance its pipeline. The company's BiTAC platform aims to address key limitations of current cancer therapies by improving tumor selectivity and reducing off-target effects. The additional funding from the financings will be crucial for moving its lead candidates into clinical trials, a critical step toward potential regulatory approval and commercialization.
For investors, this listing on Nasdaq provides an opportunity to participate in the development of next-generation antibody-based therapeutics. The successful completion of the business combination and the concurrent financings signal confidence in VERAXA's technology and strategy. However, the company faces significant risks typical of early-stage biotech firms, including clinical trial outcomes, regulatory hurdles, and competition. The long-term impact will depend on the successful advancement of its pipeline and eventual market approval.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. Voyager Acquisition Corp., the SPAC that merged with VERAXA, is a special purpose acquisition company with a mission to revolutionize the healthcare sector through mergers or business combinations. For more information, visit the company's newsroom at http://ibn.fm/VRXA.
